Beginning the Pediatric Sarcoma Journey
Dr. Leonard Wexler: The central role of private philanthropic support for clinical and basic sarcoma research cannot be overstated. Federal funds, NIH grant funds, are simply inadequate to cover this disease. It's a disease that's disproportionately seen in younger children, particularly the treatments that have more onerous long-term potential complications. And the availability of private and philanthropic support allows us to do research that might otherwise not get done. It allows for collaboration between clinical and basic researchers to try to take promising new agents and move them into the clinic more rapidly than might be possible if only federal funding was available.